Unraveling barriers to iPSC-derived CAR-T cell differentiation.

The generation of off-the-shelf CAR-T cells from TiPSCs has been hindered by the difficulty to recapitulate adaptive T cell development and lower therapeutic efficacy compared to peripheral blood CAR-T cells. Ueda et al. address these issues in a triple-engineering strategy, combining optimized CAR expression with cytolytic and persistence enhancements.